Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Electric Vehicles and Future Mobility vs 10X Genomics Inc — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $30.99, while 10X Genomics Inc trades at $56.99 (market cap $7.61B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals.
| KARS | TXG | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $58.57 |
52-Week Low | $25.59 | $11.34 |
Market Cap | — | $7.61B |
Enterprise Value | — | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KARS trades at $30.99, down 0.42% on the day, with a bullish technical signal driven by moving averages and oscillators. The stock faces resistance near $31-$32, while support lies at $30-$29. Recent news highlights global EV sales growth, with China targeting 30% NEV fleet by 2030 and Europe seeing demand surges from high fuel prices, though U.S. adoption lags.
The outlook for KARS is supported by EV industry tailwinds, but risks include competitive pressures from Chinese automakers and regulatory delays. Analyst sentiment is mixed, with technical indicators suggesting near-term consolidation. Institutional interest may hinge on sustained EV adoption trends and execution against growth targets.
TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.
Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
